| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. (NCT06646445) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2025-09-01 |
| BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients (NCT07071844) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2025-09-01 |
| PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment (NCT07028424) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2025-07-01 |
| POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric (NCT06275737) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2024-06-24 |
| First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (NCT06253611) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2024-04-16 |
| DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study (NCT06059495) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2024-01-22 |
| ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases (NCT05787197) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2024-01-09 |
| Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients (NCT05850130) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2023-11-22 |
| Combined Neuromuscular Electrical Stimulation and Nutritional Support for Advanced Gastrointestinal Cancer Patients. (NCT04906954) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2023-09-01 |
| Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study (NCT04935853) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2022-05-23 |
| Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC (NCT05310643) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2022-05-05 |
| Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients (NCT04894123) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2022-02-07 |
| Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NCT04730544) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2021-05-21 |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC (NCT03806309) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2021-04-10 |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. (NCT04348045) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2020-12-07 |
| LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy (NCT04166604) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2020-05-20 |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NCT04006262) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2019-10-23 |
| QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (NCT03828227) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2019-06-14 |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. (NCT03704480) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2018-11-09 |
| A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma (NCT03519295) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2018-07-03 |
| iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab (NCT03350126) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2017-12-04 |